Trump Moves to Require Lower Drug Prices in Medicare
- Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.
- The NIH director did the Pete & Bobby fitness challenge, but I didn't see Jay Bhattacharya do any pull-ups.
- On friday, the administration announced most-favored nation deals with nine more drugmakers.
“`html
Trump’s Drug Pricing Push: MFN Deals and Medicare Pilots
Table of Contents
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
The NIH director did the Pete & Bobby fitness challenge, but I didn’t see Jay Bhattacharya do any pull-ups. And you can decide what you think of those push-ups. Send news tips and workout advice to 753f1a1d1b5b221c191e1007061a1b35060114011b1002065b161a18 or John_Wilkerson.07 on Signal. I’ll see you again in the new year. This newsletter is taking a break for the holidays.
Trump’s Favorite Drug Pricing Policy
As his first term, Trump has promised to lower U.S. drug prices to levels charged in other rich countries. On friday, the administration announced most-favored nation deals with nine more drugmakers. Then CMS proposed two mandatory MFN pilot programs in Medicare.
Understanding the Most Favored Nation (MFN) Approach
The MFN approach, as proposed by the Trump administration, aims to tie the prices of certain drugs in the U.S. to the lowest prices paid in other developed countries. This is a important departure from the current U.S. system, where drug prices are largely resolute by market forces and negotiations between manufacturers and pharmacy benefit managers (